New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 24, 2022 - Bristol Myers Squibb announced the FDA approval of Breyanzi (lisocabtagene maraleucel).
Download PDF
Return to publications
